SIRION wins Gold Stevie business award after reporting record growth and profits

Martinsried, Germany: – Specialist viral vector supplier Sirion Biotech GmbH (SIRION) has been awarded a coveted Gold Stevie® American Business Award for its stellar performance during the past financial year.

The Gold award, awarded to the top-ranking nominee in each category as judged by 230 professionals worldwide, was recognition of SIRION’s achievement in posting record growth and profit results.

Expansion plans

SIRION Biotech GmbH was judged the Fastest Growing Company of the Year in the nomination Fastest Growing Company of the Year – Up to 100 Employees. In February, SIRION Biotech GmbH released preliminary results for FY ending December 31, 2019, showing growth of more than 50 per cent over previous year with service and licensing revenues exceeding USD 11.2m and the company’s intellectual property included in more than 10 clinical programs by leading drug developers.

SIRION also plans a continued expansion of its Paris site.

Optimized viral vector engineering

Significant factors underpinning SIRION’s success and record revenues are increasing market need for viral vectors in general and increased number of customer requests, recognizing the high quality of the SIRION’s adenovirus, lentivirus, and adenovirus-associated virus (AAV) vectors in particular.

SIRION will receive its award at the 18^th American Business Awards, conducted via a virtual awards ceremony on August 5, 2020.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titres and quantities needed for preclinical testing.

Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST^™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in several clinical trials in the US and Europe. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE^™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

SIRION Biotech International Inc. is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Learn more at: www.sirion-biotech.com

Resources

Click on SIRION results to see latest financial report.
Click on Stevie® Awards for further information about the American Business Awards.
Click on Stevie® 2020 Company Awards for complete list of all winners.